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Abstract
Background: Improvements to the outcome of adaptive immune responses could be achieved by inducing specific natural
killer (NK) cell subsets which can cooperate with dendritic cells to select efficient T cell responses. We previously reported
the induction or reactivation of T cell responses in chronic hepatitis B patients vaccinated with a DNA encoding hepatitis B
envelope proteins during a phase I clinical trial.
Methodology/Principal Findings: In this study, we examined changes in the peripheral NK cell populations occurring
during this vaccine trial using flow cytometry analysis. Despite a constant number of NK cells in the periphery, a significant
increase in the CD56bright population was observed after each vaccination and during the follow up. Among the 13 different
NK cell markers studied by flow cytometry analysis, the expression of CD244 and NKG2D increased significantly in the
CD56bright NK population. The ex vivo CD107a expression by CD56bright NK cells progressively increased in the vaccinated
patients to reach levels that were significantly higher compared to chronically HBV-infected controls. Furthermore,
modifications to the percentage of the CD56bright NK cell population were correlated with HBV-specific T cell responses
detected by the ELISPOT assay.
Conclusions/Significance: These changes in the CD56bright population may suggest a NK helper effect on T cell adaptive
responses. Activation of the innate and adaptive arms of the immune system by DNA immunization may be of particular
importance to the efficacy of therapeutic interventions in a context of chronic infections.
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Introduction
Natural Killer (NK) cells have recently been identified as crucial
actors of innate host immunity in response to a variety of
pathological challenges [1]. Their role in controlling pathogenesis
induced by infection is dual and can occur through both cytokine/
chemokine secretion and antibody dependent or natural cytotoxic
activity toward infected target cells. Human NK cells represent 5–
20% of all circulating lymphocytes and based upon their cell
surface density of CD56, two distinct populations of human NK
have been identified [2]. Most of human NK cells have low-
density expression of CD56 (CD56dim) and are the more cytotoxic
subset. In contrast, CD56bright subset that represents 10% of the
NK cells has the capacity to produce abundant cytokines. NK cells
also express several families of receptors including both inhibitory
and activating receptors [1]. These receptors, by delivering
inhibitory signals to NK cells, can prevent unwanted responses
to normal cells that express a complete set of self-MHC molecules.
Several studies reported distinct NK cell repertoire and/or NK
cell ligand expression during viral infections and their correlation
in either the control or the resistance against infections [3]. The
cross talk between NK and antigen presenting cells influences
efficiency of adaptive immune responses against virus, thus
constituting a major link between innate and adaptive immune
responses [3].
During the early phase of hepatitis B virus (HBV) infection, the
activation of innate immunity (including NK cells able to produce
large quantities of IFN-c) seems to be an important factor
determining the subsequent induction of adaptive immunity and
ultimately the outcome of HBV infection [4,5]. It now seems well
established that the differences in adaptive immunity that
characterizes chronically-infected patients and those with resolved
infection are heavily influenced by immunological events during
the initial phase of HBV replication. Activating innate immunity
could thus be of major importance when attempting to control
chronic infection. Recently, DNA-based vaccines have been
proposed as a new tool to stimulate immune responses that are
functionally exhausted during chronic viral infections [6]. In a
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previous report, we demonstrated that DNA vaccination could
specifically activate T-cell responses in HBV-carriers with chronic
active hepatitis not responding to current anti-viral therapies [7].
Plasmid DNA vaccines target antigen-presenting cells, including
dendritic cells (DC), to induce T-cell responses [8]. They contain
immunostimulatory CpG motifs which have been shown to
stimulate the innate immune system via toll-like receptor (TLR)
9 [9]. CpG motifs augment NK cell activity indirectly by inducing
the secretion of IL-12, IFN a/b and TNF-a [10,11]. During DNA
vaccination, the cross-talk between NK cells and DC could be
essential to inducing an adaptive immune response. In the present
study, we evaluated modifications to the NK cell repertoire during
a therapeutic DNA vaccination trial conducted in chronically
HBV-infected patients, and tried to correlate these modifications
to the induction of an adaptive immune response.
Methods
Participants and Study Protocol
Chronic HBV carriers, all male, with a median age of 43 years,
with biopsy-proven chronic hepatitis, active HBV replication and
no decompensated liver disease, were enrolled in a phase I clinical
trial focused on safety and whether DNA vaccination could restore
T-cell responsiveness during chronic HBV infection. All patients
were long-term HBV carriers, mostly contaminated during
childhood, and had not responded to IFN-a and/or lamivudine
therapy. The DNA vaccine was injected simultaneously into each
deltoid muscle (1 mg total DNA) at months 0, 2, 4. Five out of nine
patients received an additional injection at month 10. Blood
samples were collected before and one month after each
immunization. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1.
The historical control group of HBV-infected patients consisted
in 6 males and one female, with a median age of 45 years, with
chronic hepatitis, active HBV replication (see Table 1). They were
enrolled in a prospective study aiming at characterizing HBV-
specific immune responses and all gave their informed written
consent to participation (EUDRACT Nu 2006-004172-12).
Ethics Statement
This study was approved by the local Ethics Committee and all
study participants gave their informed, written consent to
participation, in line with French ethical guidelines. Part of the
results of the trial was previously reported [7]. Authorization was
granted by the ‘‘Comite´ Consultatif de Protection des Personnes
dans la Recherche Biome´dicale de Paris Necker’’ on November
13, 2000, approved by the French authorities (AFSSAPS
registration Nu 010030) and Biomedical Research Directorate at
Institut Pasteur. INSERM was the sponsor of the study.
DNA Vaccine
The pCMV-S2.S DNA vaccine [12] was produced under GMP
conditions by Qiagen GmbH (Hilden, Germany). This plasmid
encodes the small (S) and middle (preS2+S) proteins of the HBV
envelope (ayw subtype) under the control of the human
cytomegalovirus promoter; it has been shown to induce hepatitis
B surface (HBs)-specific T cells and anti-envelope antibodies in
mice and chimpanzees [13,14,15]. DNA was formulated in
endotoxin-free 0.9% NaCl to give a dose of 1 mg/ml.
Phenotypic Studies of NK Cells
All phenotypic studies were performed on whole blood by four-
color flow cytometry using an EPICS MCL II cytometer, and
analyzed using System II software (Coulter, Margency, France).
Lymphocytes were gated in FSC/SSC dot plot and CD3 positive
lymphocytes were eliminated from the analysis by plotting
lymphocytes in an FSC/CD3 expression dot plot. Negative CD3
cells were evaluated by the expression of CD56 and/or CD16.
The proportion of total NK cells was defined as the % of CD3-
Table 1. Clinical parameters and NK phenotype of vaccinated (HB) or untreated (CAH) patients with chronic active hepatitis.
Patienta HBeAg anti-HBe HBV DNA (pg/ml) ALAT/ASAT (IU/ml) % CD56highc
HB13 2 + ,2.5b 98/39 4
HB14 + 2 552 50/35 3
HB16 + 2 174 70/48 4
HB17 + 2 804 61/83 8
HB18 + 2 15428 227/166 2
HB21 + 2 10 222/87 4
HB22 + 2 1348 114/46 6
HB23 + 2 902 114/60 2
HB24 + 2 3968 46/28 4
CAH1 2 + 244 189/146 13
CAH2 2 + 88 198/111 1
CAH3 2 + 341 562/267 15
CAH4 + 2 3 61/41 9
CAH5 + 2 2200 73/65 5
CAH6 2 + 2 47/34 5
CAH7 2 + 3 60/44 5
aData from HB patients were collected before DNA injections.
bHBV DNA from HB13 was repeatedly detected before inclusion.
c% of the CD56high expression on NK cells as defined in Patients and Methods section.
doi:10.1371/journal.pone.0008761.t001
NK Cells and HBV DNA Vaccine
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CD56+CD16+ , CD3-CD56+CD16-, CD3-CD56-CD16+ cells in
the lymphocyte population. NK cell receptor expression analysis
was performed in CD3-CD56+CD16+/2 lymphocyte population.
The detection of natural cytotoxicity receptors (NCR) (NKp30,
NKp44, NKp46), killer inhibitory receptor (KIR) (CD158a, 158b,
158e, 158i), CD161, NKG2A, NKG2C, NKG2D and CD244 was
performed using monoclonal antibodies from Beckman Coulter
and RD Systems (Paris, France). The study of NK cell receptors
started at M1 because of limitations concerning the collection of
blood samples. CD107a (BD Biosciences, Paris, France) staining
was used as an indirect measure of cytotoxicity for cells that
underwent degranulation [16].
A historical group of untreated HBV-infected patients with
chronic active hepatitis (see Table 1) and healthy donors were
studied as controls.
IFN-c Enzyme-Linked Immunospot (ELISpot) Assay
The IFN-c ELISpot assay was used to analyze T cell responses
to HBV peptides following the in vitro expansion of PBMC as
previously described [17]. The response was considered positive if
the median number of spot-forming cells in triplicate wells was at
least twice that in control wells containing irrelevant peptide, and
at least 5 spots were detected per 26105 PBMC after background
subtraction.
Statistical Analysis
Analyses were performed using Prism software (GraphPad
Software Inc., San Diego, CA) using the nonparametric Kruskall-
Wallis test followed by Dunn’s post-test and a Mann-Whitney test
to compare two unpaired groups. A p value ,0.05 was deemed
statistically significant. Correlations between viral load, ALT and
the % of CD56bright NK cells were analyzed using the Pearson’s
correlation coefficient (r).
Results
DNA Vaccination Induces Modifications in NK Cell
Subsets in Whole Blood from HBV Carriers
DNA vaccines have been shown to activate an adaptive immune
response in rodents and humans [10]. However, the activation of
innate immunity by DNA vaccines has never been tested in
humans. We therefore studied specific changes to peripheral NK
cell populations during the follow-up of nine HBV-infected
individuals vaccinated with DNA encoding HBV envelope
proteins. As shown in Fig. 1, the mean percentage of NK cells
amongst lymphocytes and the absolute number of NK cells
remained stable over time (Fig. 1A, left panel). However, within
NK cells, a significant increase in the proportion of CD56bright NK
cells defined as CD56bright CD16- was observed one month after
the first (M1 vs. M0, p,0.02) and second (M3 vs. M2, p,0.02)
vaccine injections, suggesting that this population was triggered by
DNA vaccination (Fig. 1A, middle panel). The low number of
patients (i.e. 5) receiving the fourth DNA injection at month 10 did
not make possible to show a significant increase in the proportion
of CD56bright NK cells between M10 and M11. Nevertheless, the
percentage of the CD56bright population significantly increased
during the entire course of the vaccination protocol (p,0.005 M11
vs. M0) (Fig. 1A, right panel). The frequency of the CD56dim
population defined as CD56dimCD16+/2 among NK cells
accordingly decreased. No change in the % of CD3- CD56-
CD16+ NK cells was found in the studied patients compared to
healthy controls (not shown).
Modifications in Peripheral Blood NK Cell Repertoire from
HBV Carriers after DNA Vaccine Injection
We next tested whether modifications to subsets of NK cells
were accompanied by changes to the repertoire of NK cells. We
analyzed the expression of NK cell markers including NCR and
KIR in the two major sub-populations of NK cells; a typical
example is shown in Fig. 2A. Comparisons of blood samples taken
at months 1 and 5 showed a remarkable increase in CD244
receptor expression in the CD56bright subset.
Cell analysis of 13 different NK cell markers from 7 vaccinated
patients was performed at three different time points (M1, M5 and
M11; Fig. 2B). As controls, NK cell markers analysis was
performed on cells from a group of HBV-infected patients with
comparable clinical and virological profiles (see Table 1) and on
cells from healthy individuals. Although variations in the
expression of different receptors did exist in the studied patients,
the expression of three NK cell markers (CD244, NKG2D and
Figure 1. Follow-up of NK cells and NK subsets in whole blood during HBV DNA vaccination. Absolute values (AV) of NK cells/microL of
blood and percentages of NK cells amongst lymphocytes (left panel). Increases in the percentages of CD56bright after the first and second vaccine
injections are shown for 5 patients (middle panel). Follow-up of CD56bright and CD56dim populations among NK cells (right panel). Blood samples
were collected before the first vaccine injection (M0) and one month after the first (M1), the second (M3), the third (M5) and the fourth (M11) DNA
vaccine injections. Analysis performed at M11 included blood samples from the 9 patients whether or not they received the fourth DNA injection.
Results are shown as mean 6 SE and percentile 95.
doi:10.1371/journal.pone.0008761.g001
NK Cells and HBV DNA Vaccine
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Figure 2. Flow cytometry analysis of NK cell repertoire. A. A typical analysis is shown of NK cell subsets and receptor expression in blood
collected at two time points (M1 and M5) from one patient. Dot plots are gated in NK cells as defined in Patients and Methods section. Subsets of NK
cells are defined by the level of CD56 marker expression, as indicated (dim, bright). CD244 receptor expression in the two subsets is given as example.
Percentages of cells expressing or not the CD244 receptor in CD56bright and CD56dim subsets are indicated. B. Follow-up of NK cell marker
expression in the CD56bright (left panel) and CD56dim (right panel) subsets. Percentages of the different markers are shown for each subset. Results are
shown as mean 6 SE from seven patients. Blood samples collected at M1 (empty columns), M5 (grey columns) and M11 (black columns) time points
were analyzed. Significant differences are indicated by * p,0.05. C. Follow-up of NK cell markers and CD107a expression in the CD56bright subset.
Percentage of CD56bright NK cells expressing CD244 (upper left panel), CD161 (upper right panel), NKG2D (lower left panel) or CD107a (lower right
panel) marker is shown for individual patients. Mean values are represented by bars. Blood samples from 7 vaccinated patients collected at M1 (Vac-
M1), M5 (Vac-M5) and M11 (Vac-M11) time points were analyzed. Blood samples from 7 non-vaccinated HBV-infected patients with chronic active
hepatitis B (HBV) and from 9 healthy donors (controls) were analyzed as controls . P values are indicated on the graph by stars: **: p= 0.003;
*** p= 0.001; **** p=0.0001.
doi:10.1371/journal.pone.0008761.g002
NK Cells and HBV DNA Vaccine
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CD161) was significantly modulated at M11 in the CD56bright NK
cell subset from vaccinated patients (Fig. 2B left panel). A
significant increase in CD244 and NKG2D expression was
observed in the CD56bright NK cell subset at the later time point
(p,0.05; Fig. 2B left panel). For CD244 expression, a significant
difference was observed for CD56bright NK cells from vaccinated
patients analyzed at M1 and M5, compared to NK cells from
chronically HBV-infected control patients (p = 0.0001 and
p = 0.003, Fig. 2C upper left panel). NKG2D expression was
significantly increased on CD56bright NK cells from vaccinated
patients at M1, M5 and M11 compared to NK cells from
chronically HBV-infected control patients (p = 0.0001, Fig. 2C
lower left panel). A significant decrease in CD161 expression
was observed in the CD56bright NK cell subset (Fig. 2B left
panel) at M11 for vaccinated patients. At this later time point
CD161 expression on CD56bright NK cells from vaccinated
patients was significantly lower than on cells analyzed from
chronically HBV-infected patients or from healthy controls
(p = 0.003, Fig. 2C upper right panel).
We also assessed the ex vivo expression of the degranulation
marker CD107a, which represents an indirect measurement of the
cytotoxic capacity for T cells or NK cells. Expression of CD107a
on CD56bright NK cells from vaccinated patients at M5 and M11
was significantly higher compared to chronically HBV-infected
patients (p = 0.07 and p = 0.001 respectively; Fig. 2C lower right
panel).
In the CD56dim population, non-significant changes were
observed in NK cell receptor expression (Fig. 2B, right panel).
These results suggest that the CD56bright NK population is
specifically targeted by DNA vaccination.
Activation of the CD56bright NK Cell Subset Does Not
Correlate with HBV Viral Load
An early rise in circulating NK cells was found in acutely HBV-
infected individuals concomitant with the peak of HBV replication
with a subsequent decrease at the time of HBV-DNA drop [18].
We asked whether the increase in the CD56bright NK population
could be modulated by changes in viral load or flares in hepatitis.
We compared data from 9 patients before DNA vaccination (M0)
and 7 patients with similar virological and clinical profiles
(Table 1). However, no correlation was found (r =20.0559)
between HBV viral load and the % of CD56bright NK cells. No
correlation (r =20.0635) between ALT and the % of CD56bright
NK cells was found either. Thus the observed increase in the
CD56bright NK cell population could not be linked to viral load or
flares that are frequently observed in patients with chronic active
hepatitis.
IFN-c-Secreting T Cell Responses Correlate with
Activation of the CD56bright NK Cell Subset
We previously reported that administration of a DNA vaccine
encoding two HBV envelope proteins to chronic HBV-carriers
could induce or reactivate IFN-c-producing T cell responses
specific to HBV preS2 and S antigens [7]. In this study, S-specific
responses were found in all patients, although this response was
already detectable for two of them before DNA-injection. PreS2-
specific responses were detected in 5 out of 9 patients [7]. We then
tried to determine whether the NK cell repertoire modifications
observed in the context of HVB-DNA vaccination might be linked
to induction of the adaptive immune response. For this purpose,
we used the nonparametric Kruskall-Wallis test followed by
Dunn’s post-test to compare the number of IFN-c-secreting T cells
detected by the ELISPOT assay and the corresponding percentage
of CD56bright NK cells within the NK cell population. These
analyses were performed on S-specific T cell responses as only
these responses were found significantly higher in patients
receiving DNA injections than in unvaccinated patients
(p = 0.028, [7]). As shown in Fig. 3, the proportion of CD56bright
NK subset was positively correlated with detectable T cell
responses against HBV-S peptides, tested using the IFN-c
ELISPOT assay (r= 0.7, p,0.04). In addition, a stronger positive
correlation was observed when combined preS2- and S-specific
IFN-c-secreting T cell responses were analyzed (r= 0.92, p,0.01).
This result suggests that modifications to the NK cell repertoire
might have modulated the adaptive immune response in the
context of DNA vaccination.
Discussion
Priming of protective T cell responses has been shown in
different models of virus infection to be deeply affected by the
cross-talk between NK and DCs, where NK cells play a key
regulatory function essential for DC maturation and subsequent T
cell priming [19]. The activation of NK cells during therapeutic
intervention may therefore be important to the clearance of
infection. Here, we have demonstrated that the DNA-based
vaccination of HBV chronic carriers not only activated detectable
HBV-specific T cells in the periphery but also induced an increase
in a particular subset of NK cells. The NK cell increase was
correlated with the number of HBV-specific IFN-c-secreting T
cells activated by the DNA vaccine.
During our study, we used a DNA vaccine encoding HBV
envelope proteins (HBsAg) to activate or reactivate HBs-specific T
cells which were non-responsive during chronic HBV infection.
The activation of immune cells could be linked either to the
antigen encoded by our DNA vaccine or to the DNA vaccine
backbone. CpG sequences contained in bacterial DNA may
Figure 3. Correlation between IFN-c-secreting HBV-specific T-
cell responses and % of CD56bright NK cells. HBV S-specific T-cell
responses in patients detected using IFN-c ELISpot assay are expressed
as the number of spot-forming cells/million PBMC and plotted against
percentages of CD56bright NK cell subsets quantified at the same time
points during the follow-up of HBV DNA vaccination.
doi:10.1371/journal.pone.0008761.g003
NK Cells and HBV DNA Vaccine
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trigger the maturation of DC and other immune cells expressing
TLR9, that in turn secrete cytokines. In humans, TLR9 seems to
be expressed exclusively by pDCs and B cells, and its stimulation
induces the production of type I IFN and IL-12 [9]. These
cytokines have been shown to activate in vivo antiviral NK cell
function in mice [20]. Reports of TLR9 expression by NK cells are
conflicting but suggest that some NK subsets may express sufficient
TLR 9 for them to be directly activated by its ligand [21]. In
addition, the dual activation of DC and NK cells might facilitate
TLR-mediated activation of NK cells through DC-secreted
cytokines [22].
Although direct evidence is lacking with respect to the role of
NK cells during natural HBV infection, experiments in chimpan-
zees have suggested that the initial host response to HBV is
primarily sustained by NK and NK T cells [23,24]. In addition,
the analysis of NK cell frequencies in patients studied during the
incubation phase of acute hepatitis B has shown an early rise in
circulating NK cell levels concomitant with HBV replication and
preceding the peak of HBV-specific CD8 T cells [18]. Recently,
detailed studies on early kinetics of innate and adaptive immune
responses during initial phases of HBV infection have been
reported. These studies show an inhibition of NK cell activation
with a reduction in anti-viral cytokine secretion at the time of peak
HBV viremia [25]. The development of NK and NKT cell
response was correlated to initial viral containment and to the
subsequent induction of adaptive immune responses [5]. For
patients with chronic HBV infection, Oliviero et al. recently
reported a profound alteration in NK cell functions, with a
defective NK cytokine production in the context of a relatively
normal NK cytolytic activity [26]. Despite the lack of samples at
baseline for NK cell repertoire, our results suggest that the
CD56bright NK population and its repertoire is specifically targeted
by DNA vaccination in chronic HBV-carriers. This observation is
particularly relevant regarding the modulation of CD244 receptors
which may act as inhibitory or activating receptors, depending on
the density of its expression on NK cells. CD244 has been shown
to be internalized after stimulation and/or ligand interaction [27].
Compared to control patients CD244 expression was initially
found down-regulated in vaccinated patients, whereas at the last
time point of the follow up CD244 expression returned to basal
level. CD244 was previously found to be up-regulated in vivo by
an injection of CpG [28]. This up-regulation may contribute to
increasing NK survival and/or CD8 specific responses. One can
speculate that the later increase may be due to continuous
stimulation of NK cells and to homeostasis mechanisms as shown
in other models [29]. Modifications to NK cell receptors could be
important to the outcome of HBV infection, either by tuning the T
cell response or promoting pathways for liver damage [30].
In other models such as hepatitis C, the role of NKG2A and its
ligands has been shown to inhibit cytokine production and the
cytolytic activity of antigen-specific T cells [31,32]. In our study,
no modifications were observed to the expression of NKG2A on
NK cells. However, expression of the NKG2D receptor gradually
increased after the first DNA injection in our vaccinated patients.
Its expression was significantly higher at the end of the vaccine
protocol compared to non-vaccinated HBV-infected controls.
NKG2D functions both as an activating and a co-stimulatory
receptor having a fundamental role in the surveillance of microbial
infections and cancer [33,34]. In a mouse model, an increased
expression of NKG2D after DNA vaccination was correlated with
an improved NK and CD8 T cell response to tumor cells,
irrespective of the expression of NKG2D ligands [35,36]. In
another study, the increased expression of NKG2D was correlated
with more pronounced immune disease affecting the liver in an
HBsAg transgenic mouse model [37]. Moreover, ex vivo CD107a
expression by CD56bright NK cells progressively increased in our
vaccinated patients to reach levels that were significantly higher
compared to chronically HBV-infected controls. Increase in both
NKG2D and CD107a expression on NK cells during the
vaccination protocol are suggestive of an enhanced cytolytic
capacity. Although a 10215 fold increase in transaminase activity
was observed in two of our patients, we did not observe any major
liver complications during their follow-up [7].
CD161 engagement appears to have a complex role in the
modulation of immune functions with both activating and
inhibitory effects [38]. CD161 was involved in triggering of NK
cell cytotoxicity towards a tumor cell line [39]. In our study, the
percentage of CD56bright NK cells expressing CD161 decreased at
the latter time point. Knowing that down regulation of CD161
expression is related to the secretion of IL-2, one can speculate that
IL-2 secretion by the HBV-specific T cells may have contributed
to the observed decrease in CD161 expression [39].
We also found that the activation of IFN-c-secreting HBs-
specific T cells correlated with the increase in NK cells expressing
high levels of CD56. Several hypothesis can be put forward to
explain such observation. Recent reports suggest an important role
for NK cells in CD8+ T cell responses. On one hand, recognition
and killing of target cells by NK cells represents an important
pathway for the generation of robust antigen-specific CD8+ T and
humoral responses, in providing apoptotic cells as a source of
antigen for cross presentation to DC during viral infection [40].
On the other hand, NK-cell activation induces release of IFN-c,
which in turn can cause maturation of DC and polarize T-cell
responses [41]. Interestingly, in addition to the induction of HBV
envelope-specific T cells by the vaccine, an increase in T cells
specific to a promiscuous capsid-derived HBV epitope was found
in some patients during follow-up, although this increase was not
significant [7]. Because the vaccine used during this study encoded
envelope but not capsid proteins, this increase had previously been
attributed to a bystander effect of cytokines secreted by specifically
activated T cells. Based on our current findings, the amplification
of capsid-specific T cells might result from the increase observed in
the CD56bright subset of NK cells. IFN-c is considered to be the
prototypic NK-cell cytokine and its production by NK cells is
known to shape the Th1 immune response, activate APCs to
further up-regulate MHC class I expression [41] and exert an anti-
viral effect on HBV-infected hepatocytes [4]. It was recently
shown that both CD56dim and CD56bright NK cell subsets from
patients with chronic HBV infection display significantly lower
INF-c and TNF-a production [26]. We do not know whether
these functions were restored in our vaccinated patients because
this was not assessed in the present study due to the limited size of
available samples.
Altogether these observations are in favor of the activation of
both innate and adaptive immune responses during DNA vaccine
immunotherapy in chronic HBV carriers. This could have been
mediated directly via NK-T cell interactions and/or NK-DC
crosstalk. Activation of the innate and adaptive arms of the
immune system, and crosstalk between lymphocytes, may be of
particular importance to the efficacy of therapeutic interventions
in a context of chronic infections. Further studies would include
triggering both arms of the immune response. Decreasing viral
load was proposed to achieve a better restoration of T cell
functions during vaccine therapy. However this is currently a
matter of debate as restoration is only transient [42]. Improving
DNA vaccines by inserting a sequence involving NKG2D
receptor-ligand interaction was shown to enhance innate and
adaptive immune responses [36]. Targeting NK cells by
NK Cells and HBV DNA Vaccine
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8761
combining DNA vaccine and immune modulators such as
adjuvants (TLR agonists) and/or cytokines (e.g. IL-2, IL-15 or
IL-21) could also be an exciting option as recently proposed in
cancer immunotherapy [43].
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